Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Antisera demonstrated by precipitation and passive haemagglutination to posses antibodies specific for prostatic tissue-specific acid phosphatase have been employed to localize this isoenzyme in the prostate by indirect immunofluorescence. Antisera specific for prostatic acid phosphatase may permit the immunohistologic identification of this enzyme, thereby serving as a biological marker for metastatic prostatic cancer, where histological and/or clinical staging of the primary tumour remains questionable.
 ...
PMID:Immunohistological localization of prostatic acid phosphatase. 39 41

The reliability of bone marrow acid phosphatase determination by a spectrophotometric assay and 2 immunochemical methods was evaluated in 40 patients: 20 men with known prostatic carcinoma and 20 men of comparable age without clinical evidence of prostatic cancer. The large percentage of falsely positive results obtained by the colorimetric assay invalidates this method as the sole parameter of metastatic prostatic carcinoma.
 ...
PMID:Reliability of bone marrow acid phosphatase as a parameter of metastatic prostatic cancer. 45 10

The total and l-tartrate labile acid phosphatase were studied in 25 patients with carcinoma of prostate. The results were compared with the results from a control group. Serum acid phosphatase levels both in the control groups and in patients with prostatic cancer were lower than bone marrow acid phosphatase levels. This may be due to acid phosphatase released from blood cells during hemolysis. A positive correlation between serum and bone marrow acid phosphatase levels in patients with prostatic carcinoma was found. There was a significant rise in bone marrow acid phosphatase levels (above the normal range from the control group) in patients with advanced stage III and stage IV prostatic carcinoma with significantly increased serum levels. The levels of bone marrow acid phosphatase gave a supplementary diagnostic method in the diagnosis of prostatic carcinoma. A hypothesis that raised levels of bone marrow acid phosphatase are diagnostic of early metastasis from prostatic carcinoma is given.
 ...
PMID:Prognostic value of bone marrow acid phosphatase in prostatic carcinoma. 49 37

A national multidisciplinary study of four major systems for the histological grading of primary prostatic cancer was completed during 1978. In a series of workshops culminating in a final review, criteria of grading were critically assessed against the background of patient survival data. The overall consensus was that the Gleason system should tentatively be adopted as the pathologic reference point for classifying patients. This system can be used in conjunction with other systems. It seems definable, reproducible, reasonably simple, and has clinical relevance as judged by correlations with patient survival. Further study may demonstrate advantages from incorporation of the nuclear or cytologic characteristics of tumor cells into the Gleason system. New techniques of acid phosphatase determination, bone scans, and assessment of the regional lymph nodes should provide better staging criteria for correlation with primary tumor histology in the furture. These workshops presented a unique opportunity for representative clinicians and pathologists in the United States to express their viewpoints in a comprehensive fashion on this timely and important topic.
 ...
PMID:A report of the workshops on the current status of the histologic grading of prostate cancer. 49 23

This is a case of carcinoma of the gallbladder, which clinically, chemically, and radiographically simulated metastatic prostate cancer. Other causes of elevated serum and bone marrow acid phosphatase and axial skeletal osteoblastic metastases are reviewed.
 ...
PMID:Carcinoma of gallbladder simulating metastatic prostatic cancer. 51 14

Comparisons of the bone marrow and serum acid phosphatase values obtained by counterimmunoelectrophoresis and the Roy biochemical test were made in 72 patients with and in 13 patients without prostatic cancer. The counter-immunoelectrophoresis test, when positive at more than 1 international unit per liter, showed only 4.4% falsely positive results. The Roy biochemical test, which uses sodium thymolphthalein monophosphate as the substrate, had 65% falsely positive bone marrow acid phosphatase levels. Conflicting reports regarding the value of bone marrow acid phosphatase determinations in patients with prostatic cancer result from the use of non-specific substrates in biochemical methods for measurement and from the trauma incidental to bone marrow aspiration, which releases many non-prostatic acid phosphatase enzymes. The use of immunoassay such as counter-immunoelectrophoresis minimizes this source of error.
 ...
PMID:Bone marrow acid phosphatase in prostate cancer: an assessment by immunoassay and biochemical methods. 54 10

Two rat adenocarcinomas were physically dispersed and propagated in vitro. Epithelial and fibroblast cell lines were cloned from them and the monolayer cell lines derived therof were further characterized. The cells produced acid phosphatase in early in vitro cell passages, and later they turned negative. Fibroblast-like cells produced no tumors when implanted in syngeneic Lobund Wistar rats, but as few as 10 epithelial cells produced metastasizing adenocarcinomas in them. A third prostate tumor has yielded a line of epithelial cells which reproduced the original tumor type in inoculated rats, but the cells have not yet been characterized. Rat prostate adenocarcinomas provided a useful model system for in vitro and in vivo studies on prostate cancer and on metatasis.
 ...
PMID:In vitro propagation of prostate adenocarcinoma cells from rats. 55 62

We evaluated counterimmunoelectrophoresis for use in measuring prostatic acid phosphatase in detection of prostatic cancer. After staining for acid phosphatase, we could detect as little as 0.3 ng of purified enzyme standard complexed with antibody by this technique. However, when serum samples were used as antigen, the method was less sensitive (1.5-2.0 ng) because some of the serum proteins migrate with the phosphatase and decrease the intensity of the stain for acid phosphatase. For this reason we could not detect the phosphatase in serum samples of normal persons; only patients with moderately (or greater) increased activity in their serum showed positive results. In contrast, by radioimmunoassay as little as 1.0 ng of the phosphatase can be detected in serum.
 ...
PMID:Counterimmunoelectrophoresis in determination of prostatic acid phosphatase in human serum. 61 43

A prospective study was done to evaluate 47 patients with early stage prostatic cancer. Pelvic lymphadenectomy was combined with bone marrow acid phosphatase determination to evaluate early metastatic disease. Thirteen patients (28 per cent) had tumor in the pelvic lymph nodes. In no instance was the bone marrow acid phosphatase elevated to more than the normal value for serum by the substrate used. Combined high grade and stage tumors seemed to have an increased incidence of metastases to pelvic lymph nodes. A surprisingly high incidence of B1 lesions (5 of 21 patients or 24 per cent) had positive lymph nodes. Generally, the nodes were moderately well or well differentiated lesions. The metastases were unilateral, frequently microscopic only and involved 1 or only a few nodes. Pelvic lymphadenectomy seems to have a well defined role in the diagnostic study of early stage prostatic cancer, while bone marrow acid phosphatase determinations were of no value.
 ...
PMID:Early stage prostatic cancer investigated by pelvic lymph node biopsy and bone marrow acid phosphatase. 62 24

Bone marrow acid phosphatase has been reported to be a sensitive indicator of early bony metastasis from adenocarcinoma of the prostate. In order to evaluate this hypothesis, we measured bone marrow acid and alkaline phosphatase, lactic dehydrogenase, and calcium levels in a group of 84 patients with a variety of problems, including 18 with cancer of the prostate. We found that the bone marrow acid and alkaline phosphatase and lactic dehydrogenase were elevated and calcium was depressed in most patients. Among patients with prostate cancer, bone marrow acid phosphatase was not significantly different between those with or without bone metastases. In addition, the patients with prostatic cancer did not have higher levels of bone marrow acid phosphatase than subjects with other malignant and nonmalignant conditions. The level of acid and alkaline phosphatase, lactic dehydrogenase and calcium varied predictably with the aspiration technique used and was independent of sex, disease state or method of chemical determination. Due to this variation, we believe that bone marrow enzyme and calcium levels are of no value in the detection of metastases in patients with prostate cancer.
 ...
PMID:Lack of usefulness of bone marrow enzymes and calcium in staging patients with prostatic cancer. 63 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>